A scoping review to identify clinician reported measurement instruments of glucocorticoid toxicity for the OMERACT Glucocorticoid Impact working group
Authors' conclusion
31 candidate ClinROs were identified for measurement of physiological and psychosocial impact domains of GC impact.
Study context
- Population
- Studies of patients with inflammatory conditions treated with exogenous glucocorticoids (GCs) reporting a clinician or patient reported outcome measurestudies with ClinROs
- Participants
- 57 studies
- Outcome
- Clinician reported outcome measures (ClinROs) of GC-related adverse effects (AEs), by OMERACT GC domain
Methodological detailshand search of abstracts at major rheumatology meetings, Medline, EMBASE, CINHAL and CENTRAL searched from inception to August 2024; meeting abstracts August 2019 to August 2024
- Hand search of abstracts at major rheumatology meetings
- Medline, EMBASE, CINHAL and CENTRAL searched from inception to August 2024; meeting abstracts August 2019 to August 2024
Main finding
As reported in the abstract
Candidate ClinROs of GC impact
- Individual or grouped candidate ClinROs identified
- 31
- Studies in an AIRD population
- 20 (35.1%)
- GCs delivered systemically
- 48/57, 84.2%
- Bone fragility assessed (studies)
- 31
- Mood disturbance assessed (studies)
- 20
- Fatigue assessed (studies)
- 0
- Sleep disturbance assessed (studies)
- 2
- Appearance assessed (studies)
- 1
Original publication
A scoping review to identify clinician reported measurement instruments of glucocorticoid toxicity for the OMERACT Glucocorticoid Impact working group. Semin Arthritis Rheum. Published 19 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →